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Abstract
Objective. Mutations in the EIF1AX gene have been recently detected in a small percentage of benign and malignant thyroid 
lesions. We sought to investigate the prevalence and clinical significance of EIF1AX mutations and co-mutations in cytologi-
cally indeterminate thyroid nodules at our institution. Materials and Methods. A 5-year retrospective analysis was performed 
on thyroid nodules with a cytologic diagnosis of Bethesda category III or IV, which had undergone testing by our in-house next 
generation sequencing panel. Surgically resected nodules with EIF1AX mutations were identified, and mutation type and pres-
ence of co-mutations were correlated with histopathologic diagnosis. Results. 41/904 (4.5%) cases overall and 26/229 (11.4%) 
surgically resected nodules harbored an EIF1AX mutation. The most common histologic diagnoses were follicular thyroid car-
cinoma and follicular variant of papillary thyroid carcinoma.  11/26 (42.3%) of nodules had isolated EIF1AX mutation. Co-
mutations were found in RAS (12/26; 46.2%), TERT (5/26; 19.2%) and TP53 (2/26; 7.7%). EIF1AX mutation alone conferred a 
36.4% risk of malignancy (ROM) and 54.5% ROM or noninvasive follicular thyroid neoplasm with papillary-like nuclear fea-
tures (NIFTP), while the ROM was significantly higher in nodules with concurrent RAS (71.4%), TERT, TP53 and RAS+TERT 
(100%) mutations. Conclusion. EIF1AX mutations occur in benign and malignant follicular thyroid neoplasms. In our cohort, 
the majority of mutations occurred at the splice acceptor site between exons 5 and 6. Importantly, the coexistence of EIF1AX 
mutations with other driver pathogenic mutations in RAS, TERT and TP53 conferred a 100% ROM or NIFTP, indicating that 
such nodules require surgical removal.
Key Words: EIF1AX  Thyroid Nodule  Cytopathology  Next-Generation Sequencing.
Introduction
Up to 30% of biopsied thyroid nodules are classi-
fied as either “atypia of undetermined significance 
(AUS)/follicular lesion of undetermined signifi-
cance (FLUS)” or “follicular neoplasm (FN)/sus-
picious for follicular neoplasm (SFN)”, Categories 
III and IV respectively in The Bethesda System 
for Reporting Thyroid Cytopathology (TBSRTC) 
(1).  Because these diagnoses are not straightfor-
ward benign or malignant, and the reported risks 
of malignancy are highly variable for these catego-
ries, clinicians often struggle with the decision of 
whether or not to recommend surgical removal of 
these indeterminate nodules.  Molecular analysis, 
via multi-gene sequencing assays and gene expres-
sion classifiers, has emerged as an important sup-
plemental tool for evaluating thyroid nodules (1, 
2). At our institution, thyroid fine needle aspira-
tion (FNA) specimens with an indeterminate cyto-
logic diagnosis are routinely tested via an in-house 
next generation sequencing (NGS) panel, in order 
to provide clinicians with more information that 
may help with risk stratification and guide clinical 
management.
The most commonly known mutated genes as-
sociated with thyroid malignancies are BRAF and 
RAS. The majority of BRAF mutations are found 
in classical papillary thyroid carcinoma (PTC), 
while RAS mutations are seen in follicular vari-
ant of papillary thyroid carcinoma (FVPTC) and 
Clinical Science
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other malignant and benign follicular-patterned 
thyroid lesions (3).  More recently, mutations in 
the EIF1AX (Eukaryotic translation initiation fac-
tor 1A, X-chromosomal) gene have been detected 
in a small percentage of various types of thyroid 
cancer as well as benign thyroid nodules. The like-
lihood of malignancy in an EIF1AX-mutated thy-
roid nodule is thought to correlate with the pres-
ence or absence of co-existing mutations and with 
the position of the mutations within EIF1AX (4).
We sought to investigate the prevalence and 
clinical significance of EIF1AX mutations and co-
mutations by examining histologic outcomes of a 
large cohort of cytologically indeterminate thyroid 
nodules that underwent molecular testing and 
subsequent surgical resection.
Materials and Methods
Case Selection and Histopathologic Correlation
A database search was performed to identify 
all thyroid nodules with a cytologic diagnosis of 
Bethesda category III or IV, which had undergone 
testing by our in-house NGS panel over a 5-year 
period. Samples with EIF1AX mutations were 
identified, and the electronic medical record was 
searched to determine which nodules had under-
gone surgical resection. EIF1AX mutation type 
and presence of co-mutations were correlated with 
final histopathologic diagnosis.
Molecular Specimen Information
At the time of the FNA procedure, a separate nee-
dle pass was collected in a vial containing metha-
nol/acetic acid (3:1 ratio). Of the 987 clinical FNA 
specimens, 904 (91.6%) passed sample quality 
control and obtained molecular results.
Molecular Analysis
Mutations in EIF1AX were identified by NGS with 
a custom designed Thyroid cancer panel using Il-
lumina’s TruSeq Custom Amplicon version 1.5 
reagents as previously described (5) or CTL Vari-
antPlex Assay for Illumina Platform (ArcherDx) 
following the manufacturer’s protocol. Besides EI-
F1AX both TruSeq and Archer panels contained 
primers to amplify targeted regions of interest 
covering hotspots from additional thyroid cancer-
related genes such as BRAF, GNAS, HRAS, NRAS, 
PIK3CA, PTEN, RET, TERTpro, TP53 and TSHR. 
Libraries were sequenced on the Illumina MiSeq 
or NextSeq 500 instrument with paired end 150-bp 
sequencing. Data analysis was performed as previ-
ously described (5) for all TruSeq libraries. For all 
libraries prepared using Archer VariantPlex meth-
odology, fastq files were generated using a custom 
script and data analyses were performed using the 
CTL target region file and Archer analysis software 
version 6.2. Annotated variants were filtered and 
reported using an in-house, Web-based reporting 
application ClinMutReporter (Thomas Jefferson 
University Hospitals, Philadelphia, Pennsylvania).
Results
Patients
Among the 904 thyroid FNAs with an indetermi-
nate cytopathologic diagnosis (Bethesda Catego-
ry III or IV) that were characterized by NGS, 41 
cases (4.5%) had mutations in the EIF1AX gene. 
Histopathologic confirmation of the diagnosis was 
available in a surgical follow up specimen in 26 of 
the 41 cases (63.4%). 
Clinical & Pathologic Features
The clinical and pathologic features of the 26 pa-
tients with full diagnostic characterization are 
shown in Table 1. The mean patient age was 64 
(range: 43-81 years) and with a female preponder-
ance (female:male ratio=3.3). The mean size of the 
nodules was 2.8 cm (range: 1.1-6.3 cm). The cy-
topathologic diagnosis was Bethesda Category III 
(AUS/FLUS) in 12 (46.2%) and Bethesda Category 
IV (SFN/FN) in 14 (53.8%). As shown in Table 1 
and Figure 1, the histopathologic analysis on fol-
low up excisions included 6 neoplasms with a be-
nign diagnosis (follicular adenoma (FA)), 3 with 
Stacey M. Gargano et al: EIF1AX Mutations in Indeterminate Thyroid Nodules
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1 63 F 1.4 3 FA c.370_371delinsTT; p.G124L 26.6% Exon 6 Unknown
KRAS 
p.A59del, 5.6%
2 56 F 4.1 3 FA c.338-1_338delinsTT; p.? 3.3% A113_splice site Pathogenic -
3 43 F 1.1 3 FA c.16G>C; p.G6R 9.7% N terminus Pathogenic -
4 75 M 2.7 4 FA c.338-2A>C; p.? 7.1% A113_ splice site Pathogenic -
5 66 F 2.5 4 FA c.44G>A; p.G15D 9.7% N terminus Pathogenic -
6 63 F 2.6
4 (Hurthle 
cell type)
FA c.338-2A>T; p.? 14.1% A113_ splice site Pathogenic
-
7 76 F 5.2 3 NIFTP c.338-4_355del; p.? 16.5% A113_ splice site Pathogenic -
8 70 F 1.1 4 NIFTP c.5C>G; p.P2R 4.6% N terminus Pathogenic -





10 51 M 1.8 3 FTC c.338-1G>C; p.? 19.5% A113_ splice site Pathogenic
KRAS p.Q61R, 
8.7%









13 69 F 2.2 3 FTC c.28A>G; p.K10E 31.2% N terminus Pathogenic




15 57 F 3 4 FTC c.338-1G>C; p.? 2.1% A113_ splice site Pathogenic
NRAS p.Q61K, 
2.4%




17 69 F 3
4 (Hurthle 
cell type)
HCC c.338-1G>C; p.? 26.6% A113_ splice site Pathogenic -
18 81 M 3.7
4 (Hurthle 
cell type)
HCC c.338-1G>A; p.? 19.1% A113_ splice site Pathogenic -
19 71 F 3.5
4 (Hurthle 
cell type)
HCC c.338-1G>T; p.? 40.3% A113_ splice site Pathogenic
TP53 p.H179R, 
66.4%




21 59 F 1.8 3 EFVPTC c.338-1_339delinsACA; p.? 6.7% A113_ splice site Pathogenic
 NRAS p.Q61K, 
8.2%
22 68 F 1.3 3 EFVPTC c.338-2A>T; p.? 4.5% A113_ splice site Pathogenic
NRAS p.Q61R, 
4.3%






24 65 F 2.7 4 EFVPTC c.26G>T; p.G9V 22.2% N terminus Pathogenic
NRAS p.Q61R, 
28.9%




26 74 F 1.5 4 IFVPTC c.338-1G>C; p.? 16.7% A113_ splice site Pathogenic
YWHAG-BRAF 
Fusion
EFVPTC=Encapsulated follicular variant of papillary thyroid carcinoma; F=Female, FA=Follicular adenoma, FTC=Follicular thyroid carcinoma; HCC=Hurthle 
cell carcinoma; IFVPTC=Infiltrative follicular variant of papillary thyroid carcinoma; M=Male, NIFTP=Noninvasive follicular thyroid neoplasm with papillary-like 
nuclear features.
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a noninvasive follicular thyroid neoplasm with 
papillary-like nuclear features (NIFTP) diagnosis 
and 17 with a malignant diagnosis. 
Malignant neoplasms included follicular thy-
roid carcinoma (FTC) (N=7), encapsulated fol-
licular variant of papillary thyroid carcinoma 
(EFVPTC) with capsular invasion (N=5), Hurthle 
cell carcinoma (HCC) (N=3), and infiltrative fol-
licular variant of papillary thyroid carcinoma (IF-
VPTC) (N=2). The Bethesda Category III and IV 
cytopathologic diagnoses did not distinguish be-
tween benign and malignant thyroid neoplasms, 
as shown in Table 1.
Molecular Characterization
These 26 cases were characterized by mutations in 
the EIF1AX gene. Two distinct types of mutations 
were observed, as shown in Figure 2 and Table 1. 
A mutation at the 3’ end of the exon 6 splice site 
was observed in 17 cases and missense mutations 
in the N-terminal of the protein containing basic 
amino acids was present in 5 cases. In 4 patients 
the mutations did not fit neatly into this distribu-
tion. A duplication of the proline residue encoded 
by codon 2 was also detected, but it differs from 
the missense mutations more commonly seen in 
the N-terminal. In addition, the p.W70C muta-
tion occurs in a “mini-cluster” of mutations that 
have been seen in non-thyroid malignancies, but 
have not been reported in thyroid neoplasia in 
the COSMIC (6) or cBioPortal (7) databases. The 
p.G124L and c.429+1G>A mutations have not 
been previously reported in thyroid malignancies. 
Single mutations in the exon 6 splice site or the 
basic amino terminal tail occurred in both benign 
and malignant thyroid neoplasms. In addition to 
the abnormal EIF1AX gene, mutations in signifi-
cant tumor-associated genes occurred in 15 of the 
26 cases, and 13 of the 15 were detected in ma-
lignant neoplasms. The additional mutated genes, 
shown in Table 1, included NRAS (N=6), HRAS 
(N=3), KRAS (N=3), the common TERT promoter 
mutation (N=5), and TP53 (N=2). In 4 cases the 
TERT promoter mutation occurred with a RAS 
gene mutation and in one patient a TP53 mutation 
occurred with a mutant RAS gene. One case also 
harbored a novel YWHAG-BRAF fusion.
EIF1AX mutation alone conferred a 36.4% 
(4/11) risk of malignancy (ROM) and 54.5% (6/11) 
risk of malignancy or NIFTP, while ROM was sig-
nificantly higher in nodules with concurrent RAS 
(71.4%; 5/7), TERT, TP53 and RAS+TERT (100%) 
mutations (Table 2).
Stacey M. Gargano et al: EIF1AX Mutations in Indeterminate Thyroid Nodules
FA=Follicular adenoma; FTC=Follicular thyroid carcinoma; FVPTC=Follicular 
variant of papillary thyroid carcinoma; HCC=Hurthle cell carcinoma; 
NIFTP=Noninvasive follicular thyroid neoplasm with papillary-like nuclear 
features.
Figure 1. Prevalence of histopathologic diagnoses 
in surgically resected EIF1AX-mutated cytologically 
indeterminate thyroid nodules (N=26). 
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Discussion
EIF1AX encodes the essential, ubiquitously-ex-
pressed eukaryotic translation initiation factor 
EIF1A with 144 amino acids. As a part of the 43S 
pre-initiation complex (PIC), it binds to the capped 
mRNA, aids in localizing the start codon and ini-
tiates translation.  EIF1A protein contains a core 
RNA binding domain spanning the residues 32-95 
which is flanked on either side by highly charged 
unstructured N- and C-terminus tails (8). Origi-
nally identified in uveal melanomas, EIF1AX mu-
tations have now also been detected in a variety of 
other tumor types, including low-grade gliomas, 
lung adenocarcinoma, endometrial carcinoma, 
and various neoplastic and nonneoplastic thyroid 
lesions (4, 9-11).  Missense mutations of the first 
2-15 amino acids at the N-terminus of EIFIAX 
have been identified in several cancers (9, 12-14). 
An additional hotspot splice-site mutation (A113_
splice) in the C-terminus of the protein is thought 
to be exclusive to thyroid carcinoma (9, 11, 15). 
In our study, 4.5% of cytologically indetermi-
nate thyroid nodules (41 out of 904 total cases) 
and 11.4% (26 out of 229) of those that were surgi-
cally resected harbored an EIF1AX mutation.  Of 
these cases, the histopathologic diagnoses were 
benign neoplasm (FA) in 6/26 (23.1%), NIFTP 
in 3/26 (11.5%) and malignant neoplasm (FTC, 
HCC or FVPTC) in 17/26 (65.4%) (Table 3A).  Ka-
runamurthy et al. (4) found EIF1AX mutations in 
27/647 (4.2%) of indeterminate cytology samples, 
of which 5 had surgical follow-up information (1 
EFVPTC, 1 hyperplastic nodule (HN), and 3 FA) 
yielding an estimated ROM of 20%.  Our overall 
ROM is much higher (65.4%), and even in our 
nodules with EIF1AX mutation alone and no oth-
er coexisting mutations, the ROM is 36.4% (4/11) 
and ROM/NIFTP is 54.5% (6/11) (Table 2).  All of 
our nodules were neoplastic, though other stud-
ies have found mutations in one case of HN (4). 
Of note, the estimated ROM calculated in studies 
such as this one are overestimations of the actual 
X-axis shows the number of mutations. Green and black circles denote missense and splice site mutations respectively.
Figure 2. Distribution of EIF1AX mutations in surgically resected thyroid nodules (N=26)









EIF1AX alone 11 42.3 36.4 54.5
EIF1AX + RAS 7 26.9 71.4 85.7
EIF1AX + RAS + TERT 4 15.4 100 100
EIF1AX + RAS + TP53 1 3.8 100 100
EIF1AX + BRAF Fusion 1 3.8 100 100
EIF1AX + TERT 1 3.8 100 100
EIF1AX + TP53 1 3.8 100 100
Overall 26 100 65.4 76.9
ROM=Risk of malignancy; NIFTP=Noninvasive follicular thyroid neoplasm with papillary-like nuclear features.
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ROM, due to the impact of selection bias.  Nodules 
that undergo surgical resection are more likely to 
have suspicious pre-operative clinical findings (e.g. 
worrisome radiologic features, interval growth), 
increasing the likelihood of malignancy regardless 
of the FNA diagnosis and molecular result.
Similar to other studies, the most common 
type of EIF1AX mutation identified in our study 
was the A113_splice mutation at the intron 5/exon 
6 splice site of EIF1AX (17/26), followed by the 
missense mutations in N-terminus of the protein 
(5/26).  Previous studies have concluded that the 
A113_splice mutation, especially with co-existing 
RAS mutation, is more frequently observed in thy-
roid cancer than isolated EIF1AX mutations or 
mutations at the N-terminus hotspot of the gene 
(4, 11, 14).  In our study, 13/17 (76.5%) surgically 
resected nodules with the A113_splice mutation 
and 3/5 (60%) nodules with an N-terminal mis-
sense mutation were malignant. Of the 13 malig-
nant nodules with the A113_splice mutation, 10 
harbored co-mutations (5 harbored one co-muta-
tion and 5 harbored two co-mutations).  Of the 3 
malignant nodules with N-terminus mutation, 2 
harbored co-mutations. Please refer to Table 1 for 
details.
Four cases harbored EIF1AX mutations that 
did not belong to the 2 common types discussed 
above.  The N-terminal duplication (c.3_5dup, 
p.P2dup) was not in the COSMIC database, but 
is likely similar to the missense mutations in the 
same region. The EIF1AX p.W70C identified in the 
NIFTP case had a concurrent RAS mutation.  In 
the COSMIC database, 4 cases with this mutation 
and 3 additional missense mutations at this amino 
acid position had been reported in non-thyroid 
cancer specimens, which makes the p.W70C mu-
tation likely pathogenic.  The mutation p. G124L 
(c.370_371delinsTT), detected in a FA, has been 
reported once in the COSMIC database, in a small 
cell carcinoma of the lung.  Mutations affecting 
the same amino acid, p.G124* and p.G124V, were 
reported in a single thyroid carcinoma specimen 
(cBioPortal, sample ID TCGA-EM-A3ST-01). 
Lastly, the mutation c.429+1G>A, exon 6/in-
tron 6 splice site mutation, detected in one of our 
EFVPTC cases, has never been reported, but 7 ma-
lignant cases with mutations affecting the D143_
splice site were documented in the COSMIC data-
base. This mutation most likely affects splicing and 
hence the function of the protein.
Other studies have reported EIF1AX mutations 
co-occurring with several other driver mutations. 
Karunamurthy et al. (4) found co-mutations in 
3/11 cases (2 with NRAS and 1 with NRAS, TP53 
and TERT), all of which were malignant neo-
plasms. The TCGA study found co-mutations 
(KRAS and BRAF) in one of their 6 cases of EI-
F1AX-mutated PTC (9). Our study showed that 
EIF1AX mutations can co-occur with mutations 
in RAS, TP53 and TERT promoter (TERTp), and 
these co-mutations are associated with a very high 
ROM.  Co-existing EIF1AX and a hotspot RAS 
mutation conferred an 85.7% ROM and 100% 
ROM or NIFTP, compared to EIF1AX mutation 
alone that conferred a 36.4% ROM.  Malignancy 
risk was 100% for nodules containing co-muta-
tions in TERTp, TP53, RAS+TERTp, and BRAF fu-
sion.  Clinicians must be aware of this and should 
strongly consider surgical intervention, at least a 
lobectomy, for patients with multiple such muta-
tions in a thyroid nodule.
Key published studies on the EIF1AX muta-
tions in thyroid nodules/cancer specimens are 
summarized in Table 3. The histopathologic di-
agnoses and ROM for EIF1AX mutation positive 
specimens identified from FNA with indetermi-
nate cytology (Bethesda III and V), including our 
current study, are shown in Table 3A. The frequen-
cies of the EIF1AX mutations in different catego-
ries of thyroid nodules from surgically resected 
specimens are presented in Table 3B. 
While EIF1AX mutations were identified in 
HN, FA, and differentiated thyroid cancer (PTC 
and FTC), the percentage of specimens containing 
the EIF1AX mutations was enriched in advanced 
thyroid cancer. By combining the case numbers of 
the studies listed in Table 3B, there were 11 posi-
tive specimens for EIF1AX mutations in 97 PDTC 
(11.3%) and 9 positive in 97 ATC cases (9.3%). 
Additional co-existing mutations in PDTC and 
ATC include RAS, RAF, TERTp, TP53 mutations. 
Stacey M. Gargano et al: EIF1AX Mutations in Indeterminate Thyroid Nodules
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Table 3.  Prevalence of EIF1AX Mutations in A) Fine Needle Aspirates (FNA) and B) Surgically Removed Nodules, in Present 
and Previously Published Studies




Surgical pathology follow-up of EIF1AX-mutated FNA 
Total 
cases
HN FA NIFTP PTC FTC HCC
Karunamurthy 
et al, 2016 (4) 27/647; 4.2% 5/27 1/5; 20% 3/5; 60% - 1/5; 20%
- -
Present Study 41/904; 4.5% 26/41 - 6/26; 23.1% 3/26; 11.5% 7/26; 26.9% (FVPTC) 7/26; 26.9% 3/26; 11.5%
B. Frequency of EIF1AX Mutations in Surgically Removed Nodules
Study HN FA
Differentiated TC Undifferentiated TC
PTC FTC PDTC ATC
TCGA, 2014 (9) - -
6/402; 1.5%  (5 FVPTC; 1 mix of 
follicular & classical variant)
- - -
Kunstman et al, 2015 (16) - - - - - 3/22; 13.6%
Karunamurthy et al, 2016 (4) 1/80; 1.3% 2/27; 7.4% 2/86; 2.3% 0/53; 0% 0/4; 0% 1/4; 25%
Landa et al, 2016 (11) - - - - 9/84; 11% 3/33; 9%
Nicolson et al, 2018 (17) - - - 2/39 ; 5.1% - -
Pozdeyev et al, 2018 (15)* - - 1/89; 1.1% 2/5; 40% - 2/31; 6.5%
Simoes-Pereira et al, 2019 (14)† 0/7; 0% - 1/12; 8.3% (FVPTC)  2/9; 22.2% 0/7; 0%
ATC=Anaplastic thyroid cancer; FA=follicular adenoma; FTC=Follicular thyroid carcinoma; HCC=Hurthle cell carcinoma; HN=Hyperplastic nodule; 
NIFTP=Noninvasive follicular thyroid neoplasm with papillary-like nuclear features; PDTC=Poorly differentiated thyroid carcinoma; PTC=Papillary thyroid car-
cinoma; TC=Thyroid cancer; *Only those specimens that were sequenced on MSK-IMPACT panels were included in this table since EIF1AX is not tested by the 
FoundationOne Panels; †9 surgical specimens in this study had distinct histological type and were counted separately based on the histology. Please see the 
study by Simoes-Pereira et al. (14) for details.
Krishnamoorthy et al. (18) demonstrated EIF1AX 
A113_splice mutation increases protein synthesis 
globally and cooperates with RAS mutations to in-
crease the stability of c-MYC protein to drive thy-
roid tumorigenesis.
Among the 26 cases carrying the EIF1AX mu-
tations in our cohort, 11 cases had EIF1AX mu-
tations alone and 15 had co-existing mutations 
detected by our NGS panel.  Within the 15 co-
mutation cases, 13 were in the RAS/RAF pathway 
(including 1 case with a non-hotspot KRAS muta-
tion, p.A59del with unknown significance), and 2 
cases had a mutation either in the TERT promoter 
or the TP53 gene. When we compared the alter-
nate allele frequencies (AAF) of the EIF1AX and 
other co-existing mutations, the AAFs for the EI-
F1AX mutations were greater than (N=4) or simi-
lar to (N=10) that of other driver mutations (Table 
1). In the case with a co-existing TP53 mutation, 
the AAF for the TP53 mutation was 66% and AAF 
for the EIF1AX mutation was 40%. The apparent 
higher AAF of TP53 is likely due to a loss of het-
erozygosity (LOH) event in this case, given the 
AAF of TP53 was well over 50%. The high AAFs of 
EIF1AX mutations in comparison to that of co-ex-
isting mutations suggests that EIF1AX mutations 
represent an early event, at least in some cases, that 
promotes initiation of the thyroid tumors and ma-
lignant transformation.
Conclusion
EIF1AX mutations can occur in both benign and 
malignant thyroid neoplasms.  The type of EIF1AX 
mutation, and even more importantly, the pres-
ence or absence of co-mutations, has an impact on 
the likelihood of malignancy in an EIF1AX-mutat-
11
ed thyroid nodule.  Therefore, in the face of a cy-
tologically indeterminate thyroid nodule with an 
EIF1AX mutation detected upon molecular analy-
sis, a more detailed look at the molecular profile, 
in conjunction with the clinical and imaging find-
ings, may be helpful in predicting malignancy risk 
and determining optimal patient care.  
What Is Already Known on This Topic:
EIF1AX mutations occur in wide variety of thyroid lesions, including 
HN, FA, NIFTP, well differentiated carcinomas (FTC and FVPTC) and 
poorly differentiated carcinomas (PDTC and ATC).  Previous studies 
examining surgically resected nodules have concluded that the A113_
splice mutation, especially with co-existing RAS mutation, is more fre-
quently observed in thyroid cancer than are isolated EIF1AX mutations 
or mutations at the N-terminus hotspot of the gene.  However, there 
is limited data characterizing EIF1AX mutations in cytology samples 
from indeterminate thyroid nodules. 
What This Study Adds:
The ROM in an EIF1AX-mutated, cytologically indeterminate thyroid 
nodule may be higher than previously reported, for in our study, 36.4% 
of thyroid nodules with isolated EIF1AX mutation identified in the FNA 
sample were diagnosed as malignant neoplasms upon surgical removal. 
Furthermore, our data suggests that the presence of co-mutations, re-
gardless of the position of the EIF1AX mutation, has a significant influ-
ence on malignancy risk.  The coexistence of EIF1AX mutations with 
other pathogenic driver mutations in RAS, TERT and TP53 conferred a 
100% ROM or NIFTP in our cohort, indicating that such nodules war-
rant surgical resection. 
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